Molecular Diagnosis and Targeting for Gynecologic Malignancy


Book Description

This book summarizes the important developments in the field of cancer research, specifically uterine cervical/endometrial cancer and ovarian cancer. It highlights the recent advances in gynecologic cancer, such as next generation models of genetically engineered animal models or cancer cell lines, focusing on their significance for advancing our understanding of gynecologic cancer biology, prevention and treatment, and drug response and resistance. Cancer research in the area of gynecologic tumors has undergone an enormous transformation over the past decade, with a greater understanding of tumor biology, elucidation of novel targets for therapeutic intervention, and better recognition of genetic predisposition syndromes. At the same time, the recent advances in basic cancer research have provided key insights into all aspects of gynecologic cancer biology, including developmental pathways and the impact of lineage plasticity, understanding metastatic progression, uncovering the roles of the tumor microenvironment , exploring tumor evolution, and discovering new therapeutic approaches and mechanisms of drug sensitivity and adaptive response. Molecular Diagnosis and Targeting for Gynecologic Malignancy appeals to investigators, clinicians, residents and postdocs who are curious about new research on gynecologic malignancies. It not only presents basic and translational research, but also explores the generalizability of the evidence covering the interface between basic and clinical science. Furthermore, a number of the topics offer the basis for new ideas that have the potential to advance into the gynecologic malignancies. This book provides readers with state-of-the-art information that will help improve the lives of patients with these challenging diseases.




Noninvasive Molecular Markers in Gynecologic Cancers


Book Description

Early detection is critical for any given cancer. With the advent of the latest omics technologies, molecular markers in combination with conventional diagnostic and screening methods are emerging as next-generation early diagnostic and prognostic strategies that can allow early-stage diagnosis, resulting in more effective treatment and patient car




Diagnosis and Treatment of Rare Gynecologic Cancers


Book Description

Offering a one-stop guide to recognition and therapeutic decision making, Diagnosis and Treatment of Rare Gynecologic Cancers fills a gap in the medical literature on uncommon ovarian, uterine, cervical, and vulvovaginal cancers and trophoblastic diseases. This authoritative text, edited by Drs. Michael Frumovitz, Mario Leitao, and Preetha Ramalingam, has been authored by internationally recognized experts from top institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Each chapter covers different cancer subtypes and has been reviewed by an oncologist and a pathologist. Provides up-to-date clinical guidance on assessment and therapeutic options for patients with rare gynecologic malignancies. Presents information in a templated, easy-to-read format. Each chapter includes an introductory clinical case followed by epidemiology of disease, pathologic assessment, basic science/molecular/translational research, work-up of newly diagnosed disease, staging, treatment of newly diagnosed disease, treatment of recurrent disease, potential therapeutic targets, and a case resolution. Includes diagnostic and treatment algorithms for each form of cancer. Contains numerous anatomical figures, radiographs, photographs, and tables for quick visual reference.




Gynecological Cancers


Book Description

Facilitating the collaboration between the basic, translational, and clinical sciences, this book provides an overview of the genetic and epigenetic mechanisms underlying the formation and progression of gynecological cancers. Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development gathers all of the molecular and cellular aspects of gynecological cancer together within one volume, providing detailed and up-to-date information on the etiology, diagnosis, and treatment of gynecological cancers. Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development ​also discusses the racial and ethnic disparities in the treatment of gynecological cancers through cost effective modalities like single visit screening and diagnosis, well women clinics, and mobile clinics. Written and edited by leaders in the field, this volume within the Current Clinical Oncology series is an indispensable resource for today’s practicing oncologist.




Gynecologic Cancers


Book Description

Over the course of the last decade, the treatment of gynecologic cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of gynecologic cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues including genetics, radiology, surgery, molecular diagnostics, chemotherapy, and more. As a result, the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment. Gynecologic Cancers: A Multidisciplinary Approach to Diagnosis and Management, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses, physician assistants, physical therapists, and all health care providers involved in the treatment of gynecologic cancer. Gynecologic Cancers: A Multidisciplinary Approach to Diagnosis and Management summarizes the state-of-the-art issues related to the treatment of gynecologic cancer and describes an approach for optimal multidisciplinary care for women who have been diagnosed with or who are at higher risk to develop gynecologic cancer. About the Series: The Current Multidisciplinary Oncology series, edited by Charles R. Thomas, consolidates and integrates the varied aspects of multidisciplinary care for major topics in oncology, including breast, lung, prostrate, head and neck and more. The volumes in the Current Multidisciplinary Oncology series represent all related topic areas, including oncology, radiation oncology, pain, pathology, imaging, psychological support and the primary disease. In addition, each volume includes a chapter focusing on special populations and the disease's impact / difference on them, and discussion of future directions and quality of life issues. In addition each volume has a chapter written by a private practice oncologist. All Current Multidisciplinary Oncology titles provide: Consolidation and integration of the varied aspects of multidisciplinary care for major topics in oncology Coverage of all related topic areas, including medical and surgical oncology, radiation oncology, pain, pathology, imaging, psychological support, and the primary disease A chapter focusing on special populations and the disease's differing impact on them Discussion of quality-of-life issues




Principles and Practice of Gynecologic Oncology


Book Description

Sect. I: Etiology, prevention, and molecular biology -- Epidemiology of gynecologic cancers -- Molecular pathogenesis of gynecologic cancers -- Hereditary gynecologic cancers -- Invasion, metastasis, and angiogenesis -- Development and identification of tumor serum markers -- Cancer prevention strategies -- Preinvasive disease of the lower genital tract -- Sect. II: Diagnostic and therapeutic modalities -- Perioperative and critical care -- Surgical principles in gynecologic oncology -- Diagnostic imaging -- Biologic and physical principles of radiation oncology -- Targeted therapies in gynecologic cancers -- Principles of chemotherapy in gynecologic cancer -- Pharmacology and therapeutics in gynecologic cancer -- Immunotherapy of gynecologic malignancies -- Clinical trials methodology and biostatistics -- Cost-effective and value-based gynecologic cancer care -- Sect. III: Disease sites -- Vulva -- Vaginal cancer -- Cervix uteri -- Corpus: epithelial tumors -- Corpus: mesenchymal tumors -- Epithelial ovarian cancer -- Overian germ cell tumors -- Overian sex cord-stromal tumors -- Gestational trophoblastic disease: molar pregnancy and gestational trophoblastic neoplasia -- Sect. IV: Special management topics -- Breast cancer -- Management of infection in patients with gynecologic malignancy -- Management of surgical complications of gynecologic cancer treatment -- Management of pain -- Nutrition support of patients with gynecologic cancer -- Palliative and supportive care




Ovarian Cancers


Book Description

This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches. Surgery remains the core of ovarian cancer treatment, but its ultimate goal and the standard surgical procedure have evolved, giving rise to the question of how to label expert centers for debulking surgery. Neo-adjuvant chemotherapy is becoming more popular and is also a new field for testing novel drug combinations. Over recent years, ovarian cancer management has embraced molecular biology. It is now more correct to talk about cancers of the ovary rather than ovarian cancer, since it is not a unique disease but several entities with different molecular drivers. The significant advances in drugs targeting the microenvironment or the tumor cell DNA repair mechanisms are presented in detail together with exciting future perspectives. All these advances would not have been possible without collaborative groups such as the GINECO group in France and their integration in wider clinical research networks at the European (ENGOT) and international (GCIG) level.




Molecular Diagnosis of Cancer


Book Description

We are currently experiencing a fundamental shift in the way in which we approach the characterization of cancer. Never before has the make up of cancer tissues and individual cells been so exhaustively researched and char- terized. We are now capable of producing molecular “fingerprints” that ch- acterize the expression of all known and unknown genes within tumors and their surrounding tissues. More than 30,000 different genes may be measured in each patient’s tumor in a single experiment. Simultaneously, novel therapies that exploit the molecular roadmap have been developed and are now being offered to patients. These novel agents, such as Glivec, Herceptin, Iressa, and others, specifically target individual genes within tumors and can produce d- matic responses in some patients. These drugs are only the forerunners of a coming tidal wave of novel therapeutics that individually target specific m- ecules within cancer cells—more than 300 such agents are currently in phase I or II clinical trials. This is an exciting time for cancer specialists and patients alike. However, if we have learned anything from the past 50 or more years of research into cancer, it is that Lord Beaverbrook, in founding the British national health service in the 1950s, was frighteningly prescient when he defined the primary goal of health care to be “Diagnosis, Diagnosis, Diag- sis. ” Now, more than ever, it is essential that appropriate diagnostic methods and approaches are applied to the selection of patients for treatment.




Ovarian Cancer Biomarkers


Book Description

This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.




Gynecologic Oncology Handbook


Book Description

Known as the “blue book”, the Gynecologic Oncology Handbook: An Evidence-Based Clinical Guide is an invaluable resource for fellows, residents, and clinicians in the diagnosis and management of gynecologic cancers. Retaining the format and features that have made it a leading practical reference, this new edition has been thoroughly updated and reflects the latest advances in surgical techniques, chemotherapy protocols, breakthroughs in immunotherapies and targeted therapies, and much more. The handbook covers the full scope of disease management in a concise and accessible format. Its compact size allows it to be easily taken with the busy practitioner on the ward or in the clinic. Clear illustrations that reinforce key concepts and essential algorithms for diagnostic techniques help clinicians to a quick and accurate diagnosis. Evidence-based practices for managing gynecologic cancers are emphasized throughout the handbook including for surgical care, and for all adjuvant therapies including chemotherapy, biologics, targeted therapies, immunotherapies, and combination radiation therapy. Detailed sections on survivorship care, palliative care, and management of reproductive function and other comorbid medical conditions round out the book’s comprehensive scope. Its extensive coverage of current breakthroughs in treatment, references to critical clinical studies, and breakdown of directed gynecologic cancer workups and treatments make the Gynecologic Oncology Handbook, 3rd Edition a go-to resource within the field—including in preparation for the gynecologic oncology subspecialty certification oral board exam. Key Features: Covers all fundamentals of gynecologic oncology including workup, AJCC and FIGO staging, surgical management, chemotherapy, targeted therapy, immunotherapy, and radiation therapy treatment, comorbidity diagnosis and management, and background study data Contains insight into recently approved immunotherapies for recurrent advanced and metastatic cervical and uterine disease Provides Gynecologic Oncology Referral Parameters, Performance Status Scales, Adverse Event Grading, RECIST evaluation criteria, chemotherapy protocols, statistics, and other useful formulas Includes clinical study references, medical comorbidity algorithms, directed workups, and treatment guidelines